GALACTIC-HF Heart Failure Study

STUDY BASICS

Have you been diagnosed with heart failure? If so, you may be able to help researchers find out if an investigational study drug can make people with heart failure feel better, have to go to the hospital less often, or live longer. Participation lasts at least 2 years. Compensation is provided.

STUDY PURPOSE

Heart failure is a condition in which the heart muscle is weakened and cannot pump enough blood to the body. Symptoms of heart failure can include shortness of breath, dizziness, tiredness, nausea, swelling in the hands and feet, and others. Though treatments exist for heart failure, they often fail to control symptoms or restore quality of life. The purpose of this study is to help researchers find out if an investigational study drug called omecamtiv mecarbil can make people with heart failure feel better, need to go to the hospital less often, or live longer. An investigational drug is one that is not approved by the U.S. Food and Drug Administration (FDA).

COULD THIS STUDY BE RIGHT FOR YOU?

• Ages 18 and up
• Have a diagnosis of chronic heart failure
• Are already taking medicines that help with heart failure
• Have been hospitalized for heart failure at least once within the last year

WHAT PARTICIPANTS CAN EXPECT

Participation lasts at least two years and may last up to four years, and involves multiple visits. It is important to know that participants in this study will be randomly assigned (like the flip of a coin) to receive either the study drug, omecamtiv mecarbil, or a placebo (inactive pill that does not contain any medicine). Both the study drug and the placebo are taken by mouth. During the course of the study, participants will also provide blood samples, have electrocardiograms (ECGs), and have other tests and assessments.